Tricida Inc (NASDAQ:TCDA) has been given an average recommendation of “Hold” by the six research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $51.50.
A number of equities analysts have issued reports on TCDA shares. ValuEngine cut shares of Tricida from a “hold” rating to a “sell” rating in a report on Thursday, December 26th. Cowen set a $50.00 target price on shares of Tricida and gave the stock a “buy” rating in a report on Tuesday, October 15th. Finally, Zacks Investment Research raised shares of Tricida from a “sell” rating to a “hold” rating in a report on Thursday, December 26th.
NASDAQ TCDA traded up $0.02 during trading hours on Friday, reaching $34.86. The company’s stock had a trading volume of 328,806 shares, compared to its average volume of 245,835. The company has a current ratio of 15.48, a quick ratio of 15.48 and a debt-to-equity ratio of 0.15. The business has a 50-day simple moving average of $38.53 and a 200 day simple moving average of $35.50. Tricida has a 52 week low of $19.43 and a 52 week high of $44.30. The stock has a market cap of $1.73 billion, a PE ratio of -10.89 and a beta of 0.80.
Tricida (NASDAQ:TCDA) last issued its earnings results on Thursday, November 14th. The company reported ($0.89) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.89). As a group, equities analysts predict that Tricida will post -3.75 EPS for the current year.
In other Tricida news, SVP Dawn Parsell Otto sold 4,250 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $37.04, for a total value of $157,420.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Gerrit Klaerner sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $35.26, for a total transaction of $141,040.00. Following the completion of the transaction, the chief executive officer now directly owns 571,321 shares in the company, valued at approximately $20,144,778.46. The disclosure for this sale can be found here. Insiders sold 697,728 shares of company stock worth $27,744,447 in the last three months. 66.70% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Tricida during the third quarter valued at approximately $29,000. Bank of Montreal Can bought a new stake in shares of Tricida during the second quarter valued at approximately $72,000. Tower Research Capital LLC TRC bought a new stake in shares of Tricida during the third quarter valued at approximately $57,000. Nisa Investment Advisors LLC bought a new stake in shares of Tricida during the third quarter valued at approximately $145,000. Finally, Royal Bank of Canada raised its holdings in shares of Tricida by 356.3% during the second quarter. Royal Bank of Canada now owns 5,475 shares of the company’s stock valued at $216,000 after buying an additional 4,275 shares during the last quarter. 79.28% of the stock is currently owned by institutional investors.
Tricida Company Profile
Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.
Featured Story: What is included in the gross domestic product?
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.